Zhejiang Zhongqi Pharmaceutical

Zhejiang Zhongqi Pharmaceutical Co., Ltd. is a key subsidiary and high-tech industrialization base of the CSPC Pharmaceutical Group (石药集团), located in Haining, Zhejiang. Established in 2010, the company serves as a critical link in CSPC's "Zhongqi" innovation ecosystem, bridging the gap between drug discovery and large-scale commercial production. It is responsible for the manufacturing of several of the group's flagship innovative products, including Butylphthalide (NBP) for ischemic stroke and advanced liposomal therapies like Mitoxantrone Liposome. The company's facilities are built to international GMP standards, supporting the production of both active pharmaceutical ingredients (APIs) and finished dosage forms. Zhejiang Zhongqi plays a vital role in CSPC's expansion into oncology, cardiovascular, and metabolic disease markets.